A Favorable Benefit-Risk Balance Maybe Expected with Replication-Defective Adenovirus-Mediated Interferon Gene Therapy for Cancer Treatment.
作者信息
Qin Albert
机构信息
Medical Research and Clinical Operations, PharmaEssentia Corporation, Taipei, Taiwan.
出版信息
Hum Gene Ther. 2023 Apr;34(7-8):339-340. doi: 10.1089/hum.2023.028.
Abstract
摘要
相似文献
1
A Favorable Benefit-Risk Balance Maybe Expected with Replication-Defective Adenovirus-Mediated Interferon Gene Therapy for Cancer Treatment.
Hum Gene Ther. 2023 Apr;34(7-8):339-340. doi: 10.1089/hum.2023.028.
2
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.
Curr Gene Ther. 2013 Dec;13(6):421-33. doi: 10.2174/1566523213666131125095046.
3
Advances in adenovirus-mediated p53 cancer gene therapy.
Expert Opin Biol Ther. 2013 Nov;13(11):1569-83. doi: 10.1517/14712598.2013.845662.
4
Concepts in Oncolytic Adenovirus Therapy.
Int J Mol Sci. 2021 Sep 29;22(19):10522. doi: 10.3390/ijms221910522.
5
Adenovirus vectors deleted for genes essential for viral DNA replication.
Front Biosci. 2005 May 1;10:1146-55. doi: 10.2741/1607.
6
Targeting vectors for cancer gene therapy.
Front Biosci (Elite Ed). 2009 Jun 1;1(1):332-40. doi: 10.2741/E32.
7
Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy.
Mol Ther. 2007 Jun;15(6):1121-8. doi: 10.1038/sj.mt.6300128. Epub 2007 Mar 27.
8
A Favorable Benefit-Risk Balance Maybe Expected with Replication-Defective Adenovirus-Mediated Interferon Gene Therapy for Cancer Treatment, by Qin 2023;34(7-8):339-340; doi: 10.1089/hum.2023.028.
Hum Gene Ther. 2023 Jul;34(13-14):662. doi: 10.1089/hum.2023.028.correx. Epub 2023 May 8.
9
Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.
Breast Cancer Res. 2009;11(4):R53. doi: 10.1186/bcr2342. Epub 2009 Jul 27.
10
Transductional targeting of adenovirus vectors for gene therapy.
Cancer Gene Ther. 2006 Sep;13(9):830-44. doi: 10.1038/sj.cgt.7700928. Epub 2006 Jan 27.
引用本文的文献
1
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera.
Pharmacol Res Perspect. 2025 Jun;13(3):e70109. doi: 10.1002/prp2.70109.
2
Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b.
Front Pharmacol. 2024 Sep 24;15:1455979. doi: 10.3389/fphar.2024.1455979. eCollection 2024.
3
An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1.
Front Oncol. 2023 Apr 27;13:1173467. doi: 10.3389/fonc.2023.1173467. eCollection 2023.
本文引用的文献
1
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.
Front Oncol. 2023 Jan 19;13:1109866. doi: 10.3389/fonc.2023.1109866. eCollection 2023.
2
Direct evidence that IFN-beta functions as a tumor-suppressor protein.
J Interferon Cytokine Res. 2002 Nov;22(11):1089-98. doi: 10.1089/10799900260442511.
3
Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models.
Mol Ther. 2001 Oct;4(4):356-64. doi: 10.1006/mthe.2001.0464.
4
Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice.
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14411-6. doi: 10.1073/pnas.95.24.14411.
Zotero 插件